The Convergence of Stem Cell Technologies and Phenotypic Drug Discovery
Authors/Creators
- 1. Department of Chemical Biology, Max Planck Institute of Molecular Physiology, 44227 Dortmund, Germany
- 2. ISAR Bioscience GmbH, Institute for Stem Cell & Applied Regenerative Medicine Research, 82152 Planegg, Germany
- 3. Department of Cell and Developmental Biology, Max Planck Institute for Molecular Biomedicine, 48149 Münster, Germany/Medical Faculty, University of Münster, Domagkstrasse 3, 48149 Münster, Germany
- 4. Department of Chemical Biology, Max Planck Institute of Molecular Physiology, 44227 Dortmund, Germany, Faculty of Chemistry and Chemical Biology, TU Dortmund, Otto-Hahn-Str. 4a, 44227 Dortmund, Germany
- 5. Department of Cell and Developmental Biology, Max Planck Institute for Molecular Biomedicine, 48149 Münster, Germany
Description
Recent advances in induced pluripotent stem cell technologies and phenotypic screening shape the future of bioactive small-molecule discovery. In this review we analyze the impact of small-molecule phenotypic screens on drug discovery as well as on the investigation of human development and disease biology. We further examine the role of 3D spheroid/organoid structures, microfluidic systems, and miniaturized on-a-chip systems for future discovery strategies. In highlighting representative examples, we analyze how recent achievements can translate into future therapies. Finally, we discuss remaining challenges that need to be overcome for the adaptation of the next generation of screening approaches.
Notes
Files
Restricted
The record is publicly accessible, but files are restricted to users with access.
Request access
If you would like to request access to these files, please fill out the form below.
You need to satisfy these conditions in order for this request to be accepted:
Green Open Access (Subscription)
You are currently not logged in. Do you have an account? Log in here